000 | 01919 a2200529 4500 | ||
---|---|---|---|
005 | 20250516121613.0 | ||
264 | 0 | _c20130729 | |
008 | 201307s 0 0 eng d | ||
022 | _a1098-6596 | ||
024 | 7 |
_a10.1128/AAC.00877-12 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWarren, Cirle A | |
245 | 0 | 0 |
_aVancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. _h[electronic resource] |
260 |
_bAntimicrobial agents and chemotherapy _cFeb 2013 |
||
300 |
_a689-96 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural | ||
650 | 0 | 4 |
_aAminoglycosides _xtherapeutic use |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAnti-Bacterial Agents _xtherapeutic use |
650 | 0 | 4 |
_aBacteroides _xgenetics |
650 | 0 | 4 |
_aCecum _xmicrobiology |
650 | 0 | 4 |
_aClostridioides difficile _xdrug effects |
650 | 0 | 4 |
_aClostridium Infections _xdrug therapy |
650 | 0 | 4 |
_aDNA, Bacterial _xisolation & purification |
650 | 0 | 4 |
_aEnterocolitis, Pseudomembranous _xdrug therapy |
650 | 0 | 4 |
_aFeces _xmicrobiology |
650 | 0 | 4 | _aFidaxomicin |
650 | 0 | 4 |
_aIntestines _xdrug effects |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aMetronidazole _xtherapeutic use |
650 | 0 | 4 | _aMice |
650 | 0 | 4 | _aMice, Inbred C57BL |
650 | 0 | 4 | _aNitro Compounds |
650 | 0 | 4 | _aRecurrence |
650 | 0 | 4 |
_aThiazoles _xtherapeutic use |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aVancomycin _xtherapeutic use |
700 | 1 | _avan Opstal, Edward J | |
700 | 1 | _aRiggins, Mary S | |
700 | 1 | _aLi, Yuesheng | |
700 | 1 | _aMoore, John H | |
700 | 1 | _aKolling, Glynis L | |
700 | 1 | _aGuerrant, Richard L | |
700 | 1 | _aHoffman, Paul S | |
773 | 0 |
_tAntimicrobial agents and chemotherapy _gvol. 57 _gno. 2 _gp. 689-96 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1128/AAC.00877-12 _zAvailable from publisher's website |
999 |
_c22260018 _d22260018 |